The PhD in Cancer Immunology and Immunotherapy at the University of South Florida trains researchers to study how the immune system recognizes cancer and how to translate that knowledge into new therapies.Students work across immunology, oncology, molecular biology, genomics, and translational medicine through lab-based research, advanced coursework, and mentorship from faculty with active research programs.
The PhD in Cancer Immunology and Immunotherapy at the University of South Florida equips students with the knowledge and skills to investigate how the immune system identifies and combats cancer. This program focuses on translating scientific findings into innovative therapies that can improve patient outcomes.
Students engage in a multidisciplinary approach encompassing immunology, oncology, molecular biology, genomics, and translational medicine. The program emphasizes hands-on laboratory research, advanced academic coursework, and mentorship from faculty members who are active in their research fields.
The curriculum is structured around advanced coursework and a research-driven dissertation. Students are expected to complete core and elective courses while advancing through laboratory training and research milestones under faculty guidance.
Coursework may include:Students can choose additional electives or special topics based on their interests and faculty availability, which may include areas like tumor microenvironment biology, immune profiling, translational study design, and computational analysis.
Graduates of the PhD program in Cancer Immunology and Immunotherapy are well-prepared for a range of careers in academia, industry, and healthcare. Potential pathways include roles in research institutions, pharmaceutical companies, biotech firms, and governmental agencies. The demand for experts in cancer research and immunotherapy continues to grow, offering numerous opportunities to contribute to advancements in cancer treatment and patient care.
Shortlist scholarships and plan your application — free guidance from our advisors.